Biden Races Clock On Health Regulations With Eye On Potential Trump Return

President Biden’s administration is working overtime to ensure his health care priorities are protected from a potential second Trump White House. In recent weeks, regulatory agencies have been racing against the clock to finalize some of their most consequential policies.

Read More

Final Prior Authorization Rules Look to Streamline the Process, but Issues Remain

As concerns continue to be raised about consumer barriers to care resulting from prior authorization requirements, the federal government issued a final regulation aimed at streamlining and automating the prior authorization process and improving transparency for certain payers.

Read More

California Floats Extending Health Insurance Subsidies to All Adult Immigrants

The same health advocates who fought for the Medi-Cal expansion say the next step in achieving health equity is expanding Covered California, the state’s ACA marketplace, to all immigrant adults by passing AB 4.

Read More

Biden Team’s Tightrope: Reining In Rogue Obamacare Agents Without Slowing Enrollment

President Joe Biden counts among his accomplishments the record-high number of people, more than 21 million, who enrolled in Obamacare plans this year. Behind the scenes, however, federal regulators are contending with a problem that affects people’s coverage: rogue brokers who have signed people up for Affordable Care Act plans, or switched them into new ...

Read More

Trump, Biden Admin Policy Heads Agree: Price Transparency Is Here To Stay

Price transparency and the No Surprises Act are still in their infancy, but providers and health plans would be smart to comply now to avoid facing unnecessary penalties, warned President Trump’s former Health and Human Services Secretary Alex Azar in a recent virtual summit. The former policymaker said the wheels set in motion during his ...

Read More

Healthcare And Drugmaker Groups Seek To Revive Challenge To US Drug-Pricing Law

Healthcare and drug industry groups on Wednesday urged a U.S. appeals court to revive their challenge to a law requiring manufacturers to negotiate the prices of some drugs with the U.S government’s Medicare health insurance program or pay heavy penalties. Pharmaceutical Research and Manufacturers of America (PhRMA), the Global Colon Cancer Association and the National ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square